Abstract:Several studies have demonstrated the efficacy of localized in situ transplantation of stem/progenitor cells for tissue/organ regeneration. However, the possible limitations of such an approach have largely been overlooked. This is contrary to the intrinsic physiological process of tissue/organ regeneration in vivo, which is thought to involve the mobilization of stem/progenitor cells resident within the tissue/organ itself, as well as from ectopic sites, in particular the bone marrow. Signaling pathways and other molecular processes within stem/progenitor cells transplanted in situ may not be primed to achieve optimal tissue/organ regeneration, and may even be confused by the sudden rapid transition in the cellular microenvironment encountered during transplantation. To overcome these putative limitations, a possible strategy may be to combine transfusion of stem/progenitor cells into the peripheral circulation with localized transplantation in situ at the site of tissue/organ damage. This could better replicate the natural physiological process of tissue/organ repair in vivo. Possible synergistic interactions between the transplanted stem/progenitor cells in situ with migratory transfused cells from the peripheral circulation may further enhance tissue/organ regeneration. The transfused stem/progenitor cells may be induced to home in on a damaged tissue/organ, via the controlled release of specific cytokines or chemokines (i.e., SDF-1) emanating from that particular tissue/organ. There are a number of possible ways to achieve this. For example, the transplanted cells may be delivered on tissue-engineered scaffolds that are designed for the controlled release of specific homing factors such as SDF-1. Another alternative may be to stimulate or genetically modulate the transplanted cells to copiously secrete homing factors such as SDF-1, to encourage the migration and homing of transfused cells within the peripheral circulation. At the same time, it may also be advantageous to pre-stimulate the transfused cells to strongly express surface receptors specific to homing factors such as SDF-1, in particular CXCR-4. More rigorous investigations should be carried out on the possible strategy of combining in situ transplantation of stem/progenitor cells with transfusion into the peripheral circulation, together with induced homing of the transfused cells to the site of organ/tissue damage. This may possibly result in better efficacy for some, but not all models of tissue/organ regeneration.

Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration

Combining Transfusion of Stem/progenitor Cells into the Peripheral Circulation with Localized Transplantation in Situ at the Site of Tissue/organ Damage: A Possible Strategy to Optimize the Efficacy of Stem Cell Transplantation Therapy

Statin and Stromal Cell-Derived Factor-1 Additively Promote Angiogenesis

Vascular Regeneration by Stem/Progenitor Cells.

Endothelial progenitor cells: precursors for angiogenesis

Vascular Repair by Endothelial Progenitor Cells

Characterizations and Roles of Endothelial Progenitor Cells in Vascular Biology

Endothelial precursors in vascular repair

Synergistic actions of hematopoietic and mesenchymal stem/progenitor cells in vascularizing bioengineered tissues.

Stem/Progenitor cells in vascular regeneration

Endothelial Progenitor Cells and In-stent Restenosis.

Endothelial Repair by Stem and Progenitor Cells

State of the field: cellular and exosomal therapeutic approaches in vascular regeneration

Progenitor Cells in Vascular Repair

A Combination of Distinct Vascular Stem/Progenitor Cells for Neovascularization and Ischemic Rescue.

Progenitor cells in vascular disease.

Endothelial progenitor cells for fabrication of engineered vascular units and angiogenesis induction

Frontiers in nephrology: the evolving therapeutic applications of endothelial progenitor cells

Progenitor Cells in Vascular Disease

Endothelial Progenitor Cells and Their Application in Tissue Engineering

Application of stem cells in engineered vascular graft and vascularized organs